A new study suggests that a urine-based biomarker test shows promise in forecasting bladder cancer treatment response, which ...

SUZHOU, China, Feb. 26, 2026 /PRNewswire/ -- Intravesical BCG is the standard of care (SOC) for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC) patients. However, the scarcity of BCG ...

Bladder cancer arises from the lining of the bladder, the organ that stores urine, and is one of the most common cancers in the United States. Most patients are diagnosed at an early stage called ...

A refined liquid biopsy that accounts for age-related background mutations has enabled clinicians to identify patients with non-muscle invasive bladder cancer who could benefit from ...

Tokyo BCG is not inferior to TICE, and may help ease the BCG shortage. For treatment of high-grade (HG) non-muscle invasive bladder cancer (NMIBC), the Bacillus Calmette-Guérin (BCG) strain Tokyo-172 ...

ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS with or without papillary tumors. FDA interactions centered on updated ...

Trimodal therapy versus radical cystectomy in muscle-invasive bladder cancer: The overlooked influence of informative censoring—A systematic review and meta-analysis. This is an ASCO Meeting Abstract ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today ...

ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) ...

Combat Medical (Combat), a medical device company optimizing the delivery and efficacy of cancer therapeutics, today announced it has raised £2.6 million in the first close of a Series A financing to ...